Recall Record

Wilmington, MA, United States

Azurity Pharmaceuticals, Inc. recalls

4 recalls recorded since 2018, most recently on 4 January 2024. None are listed as ongoing. Status and classification are as published by the FDA.

Recalls4
Ongoing (FDA)0
Terminated or completed4
Class I (FDA)2

Terminated Class I Drugs

Recall started
4 January 2024
Terminated
18 September 2024
Reason
Labeling: Label Mix-up
Distribution
USA nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-0323-2024

Terminated Class III Drugs

Recall started
8 December 2023
Terminated
24 April 2024
Reason
Failed Impurities/Degradation Specifications: Out of specification Impurity C (4,5-desisopropylidene topiramate) result observed during routine stability testing at 18 months.
Distribution
USA nationwide.
Initiated
Voluntary: Firm initiated
Recall number
D-0213-2024

Terminated Class II Drugs

Recall started
15 February 2023
Terminated
4 December 2023
Reason
cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.
Distribution
US Nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-0489-2023

Terminated Class I Drugs

Recall started
24 August 2021
Terminated
12 May 2022
Reason
Product Mix-up: Incorrect diluent component included in the kit.
Distribution
USA nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-0003-2022

A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.